SYSTEMATIC REVIEW article
Front. Med.
Sec. Dermatology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1591787
This article is part of the Research TopicNew Insights into Inflammation Driven Autoimmune Skin Disorders: Trends and ChallengesView all articles
Efficacy and Safety of Mirikizumab (LY3074828) in Chronic Plaque Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Provisionally accepted
Taimoor Ashraf1
Anand Kumar Malani2Dileep Kumar2
Raja Subhash Sagar2Sahil Raj3Payal Kumari3Aanchal Kumari4
Simran Bajaj5Muhammad Abdul Basit6Muhammad Murad4
Vikash Kumar4
Ayush Kumar7*- 1Nishtar Medical University, Multan, Punjab, Pakistan
- 2Liaquat University of Medical & Health Sciences, Jamshoro, Sindh, Pakistan
- 3Bahria University Health Sciences, Karachi, Punjab, Pakistan
- 4Jinnah Sindh Medical University, Karachi, Sindh, Pakistan
- 5Shaheed Mohtarma Benazir Bhutto Medical University, Larkana, Sindh, Pakistan
- 6Dow Medical College, Dow University of Health Sciences, Karachi, Punjab, Pakistan
- 7Vayodha Hospitals, Kathmandu, Nepal
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Chronic plaque psoriasis is a persistent inflammatory skin condition characterized by erythematous, scaly plaques, significantly impairing the quality of life of affected individuals. Mirikizumab, a humanized monoclonal antibody targeting interleukin-23 (IL-23) p19 subunit, has shown promising efficacy in managing moderate-to-severe cases of this disease. This meta-analysis aims to evaluate the efficacy and safety of mirikizumab in comparison to placebo or other active treatments in this patient population.A systematic review of randomized controlled trials (RCTs) was conducted. Eligible studies were identified through searches of major databases. The primary endpoint was clinical response measured by Psoriasis Area and Severity Index (PASI) improvement. Safety outcomes were evaluated based on the frequency of events. Data were pooled using a random-effects model to calculate relative risk and mean differences across studies.Mirikizumab significantly increased the rates of achieving PASI 100, PASI 90, and PASI 75 compared to placebo. Mirikizumab also demonstrated superior efficacy in various secondary outcomes compared to placebo. Safety analysis indicated no significant differences in overall treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs), although upper respiratory tract infections occurred more frequently in the mirikizumab group.Mirikizumab demonstrated a significant improvement in PASI scores compared to placebo and other treatments for chronic plaque psoriasis. Its IL-23 inhibition mechanism suggests a promising therapeutic option with a favorable safety profile. Further research could solidify its position in long-term psoriasis management.
Keywords: Psoriasis, Plaque psoriasis, mirikizumab, Interleukin-23, psoriasis area and severity index
Received: 11 Mar 2025; Accepted: 25 Jun 2025.
Copyright: © 2025 Ashraf, Kumar Malani, Kumar, Sagar, Raj, Kumari, Kumari, Bajaj, Basit, Murad, Kumar and Kumar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ayush Kumar, Vayodha Hospitals, Kathmandu, Nepal
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.